Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share

Scilex Holding Co

Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.
RoyaltyVest pays Scilex Pharma 50% of net revenue from ex-US sales; annual $200K commitment until first regulatory approval.
Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one Major Market Country within 18 months.
Scilex Pharma grants exclusive, non-transferable license; Scilex Holding Company provides parent guarantee for performance.
Agreement effective February 22, 2025, replacing the October 2024 Rest of World License Term Sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.